Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies
-
Abstract Number: 3219
Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
-
Abstract Number: 3220
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial